Search results for "Partial"

showing 10 items of 1477 documents

Extracorporeal circuit heparinization in selective low density lipoprotein apheresis: changes in patient hemostasis and low molecular weight heparin …

1993

Treatment by low density lipoprotein (LDL) apheresis using dextran sulfate columns (DSC) leads to hemostasis alterations with prolonged activated partial thromboplastin time (APTT) of more than 120 seconds. In order to explain this hypocoagulability, we studied hemostasis parameters both in patients and in the extracorporeal circulation (ECC). Hemostasis changes are first related to unfractionated heparin (UFH)—needed to avoid circuit coagulation—which leads to high residual heparinemia in the patient (more than 3 times the recommended level for therapeutic use). Second, the hypocoagulability is induced by a coagulation factor decrease (primarily factors V, VIH, and X) mainly due to an adso…

Adultmedicine.medical_specialtyExtracorporeal Circulationmedicine.drug_classLow molecular weight heparinHyperlipoproteinemia Type IIInternal medicinemedicineHumansHemostasismedicine.diagnostic_testbusiness.industryExtracorporeal circulationAnticoagulantDextran SulfateNadroparinHematologyGeneral MedicineHeparinMiddle AgedBlood Coagulation FactorsSurgeryLipoproteins LDLApheresisLDL apheresisHemostasisCardiologyBlood Component RemovalbusinessPartial thromboplastin timemedicine.drugJournal of clinical apheresis
researchProduct

The impact of del Nido cardioplegia solution on blood morphology parameters

2021

Background: Crystalloid cardioplegic solutions are believed to reduce hemoglobin significantly and increase the transfusion rate. However, recent reports indicate that the del Nido cardioplegia may preserve blood morphology parameters. Methods: In “The del Nido versus cold blood cardioplegia in aortic valve Replacement” trial patients undergoing aortic valve replacement were randomized into the del Nido (DN) or cold blood cardioplegia (CB) group. For the subanalysis, patients who underwent blood transfusions were excluded from the study. Red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count and platelet (PLT) count were measured before the surgery, 24-, 48-, and 96 hours post…

Advanced and Specialized Nursingmedicine.diagnostic_testbusiness.industryGeneral Medicinemedicine.diseaseRed blood cellmedicine.anatomical_structureAortic valve replacementBlood productAnesthesiaWhite blood cellCoagulopathyMedicineRadiology Nuclear Medicine and imagingPlateletHemoglobinCardiology and Cardiovascular MedicinebusinessSafety ResearchPartial thromboplastin timePerfusion
researchProduct

Thermodynamic Behavior of Non-Ionic Tri-block Copolymers in Water at Three Temperatures

2006

Apparent molar volumes (V Φ) of aqueous solutions of some copolymers, based on ethylene oxide (EO) and propylene oxide (PO) units, were determined as functions of concentration at three temperatures. Viscosity measurements were also carried out on some of these systems. The effects studied include how the molecular architecture and the molecular weight affect the aggregation of the copolymer, keeping constant the EO/PO ratio. Modeling of the volumetric data yielded the partial molar volume of the copolymer in the standard (V°) and the aggregated (V M) states, as well as the equilibrium constant for micellization and the aggregation number. Analysis of the viscosity data supported the insigh…

Aggregation numberAqueous solutionEthylene oxideChemistryBiophysicsAnalytical chemistryPartial molar propertyBiochemistryGibbs free energychemistry.chemical_compoundsymbols.namesakeMolar volumePolymer chemistryCopolymersymbolsDensity . Viscosity Apparent molar volumes Copolymers Gibbs energy of micellizationPhysical and Theoretical ChemistryMolecular BiologyEquilibrium constantJournal of Solution Chemistry
researchProduct

Mass action model for solute distribution between water and micelles. Partial molar volumes of butanol and pentanol in dodecyl surfactant solutions

1986

The densities of 1-butanol and 1-pentanol were measured in aqueous solutions of dodecyltrimethylammonium bromide and dodecyldimethylamine oxide and the partial molar volumes at infinite dilution of the alcohols in aqueous surfactants solutions were obtained. The observed trends of this quantity as a function of the surfactant concentration were rationalized using a mass-action model for the alcohol distribution between the aqueous and the micellar phase. At the same time, the model was revised to account for the alcohol effect on the surfactant micellization equilibrium. The partial molar volume of alcohols in the aqueous and in the micellar phases and the ratios between the binding constan…

Aggregation numberChemistryButanolInorganic chemistryBiophysicsPartial molar propertyPrimary alcoholBiochemistryMicellechemistry.chemical_compoundMolar volumeCritical micelle concentrationMicroemulsionPhysical and Theoretical ChemistryMolecular BiologyJournal of Solution Chemistry
researchProduct

Thermodynamic properties of alcohols in a micellar phase. Binding constants and partial molar volumes of pentanol in sodium dodecylsulfate micelles a…

1984

Densities of the ternary system water-sodium dodecylsulfate (NaDS)-pentanol and of the binary systems butanol-octane and pentanol-octane were measured at 15, 25, and 35 °C. The apparent molar volume of pentanol in the ternary system was analyzed using a mass-action model for the alcohol distribution in micellar solutions. The partial molar volume of alcohol bound to the micelles and the ratio between the binding constant and the aggregation number of the surfactant are calculated. The partial molar volume binding constant, is discussed in terms of solubilization sites of the alcohol in the micelles whereas the binding constant is compared with that derived from the Nernstian partition const…

Aggregation numberTernary numeral systemChemistryInorganic chemistryBiophysicsPartial molar propertyBiochemistryBinding constantMicelleMolar volumeCritical micelle concentrationMicellar solutionsPhysical chemistryPhysical and Theoretical ChemistryMolecular BiologyJournal of Solution Chemistry
researchProduct

Diagnosis and management of asthma in the elderly.

2013

Bronchial asthma is one of the most common chronic diseases worldwide, and by definition not expected to recover with aging. However, the concept that asthma can affect older individuals has been largely denied in the past. In clinical practice, asthma that occurs in the most advanced ages is often diagnosed as COPD, thus leading to undertreatment or improper treatment. The heterogeneity of clinical and functional presentation of geriatric asthma, including the partial loss of reversibility and of the allergic component, contributes to this misconception. A large body of evidence has accumulated demonstrating that the prevalence of asthma in the most advanced ages is similar to that in youn…

Agingmedicine.medical_specialtyComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Human lungMedication AdherenceOlder patientsPartial lossInternal MedicinemedicineHumansAnti-Asthmatic AgentsIntensive care medicineAsthmaAgedCOPDbusiness.industryAsthma treatmentAge Factorsmedicine.diseaseComorbidityLung functionAsthmarespiratory tract diseasesClinical Practicemedicine.anatomical_structurePhysical therapybusinessAirway inflammationEuropean journal of internal medicine
researchProduct

Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat.

2009

The anticonvulsant effect of cannabinoids (CB) has been shown to be mediated by the activation of the CB(1) receptor. This study evaluates the anticonvulsant activity of (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN55,212-2, CB agonist) alone or preceded by the administration of N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, selective CB(1) antagonist) in an experimental in vivo model of complex partial seizures (maximal dentate gyrus activation - MDA) in the rat. WIN55,212-2 (21mgkg(-1)) exerted an anticonvulsant effect, significantly reduced by the pre-treatme…

AgonistAM251Malemedicine.medical_specialtyCannabinoid receptormedicine.drug_classmedicine.medical_treatmentMorpholinesNaphthalenesSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1Internal medicineControlCannabinoid Receptor ModulatorsmedicineAnimalsRats WistarReceptorEpilepsyChemistryCannabinoidsGeneral NeuroscienceAntagonistBrainmedicine.diseaseCalcium Channel BlockersElectric StimulationBenzoxazinesRatsDisease Models AnimalMaximal dentate activationAnticonvulsantEndocrinologySettore BIO/14 - FarmacologiaRatPyrazolesAnticonvulsantsCannabinoidEpilepsies Partialmedicine.drugNeuroscience letters
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

The In Vitro Pharmacological Profile Of LAS100977 - A Potent, Selective And Long-acting Beta-2 Receptor Agonist

2010

AgonistLong acting betabusiness.industrymedicine.drug_classMedicineInverse agonistSelective receptor modulatorPharmacologyReceptorbusinessPartial agonistIn vitroD34. NOVEL THERAPEUTIC OPTIONS IN AIRWAYS DISEASE
researchProduct

Role of CB2 receptors and cGMP pathway on the cannabinoid-dependent antiepileptic effects in an in vivo model of partial epilepsy.

2014

This study aimed at providing an insight on the possible role of cannabi-noid (CB) type 2 receptors (CB2R) and cGMP pathway in the antiepileptic activity ofWIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone, a non-selective CB agonist, in the maximal dentate activation (MDA) model of partial epilepsy in adult male rats. We evaluated the activity of a CB2 antagonist/inverse agonist AM630, [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone or 6-iodopravadoline, alone or in co-administration with WIN 55,212-2. Also, in the MDA model it was investigated the co-treatment of WIN55,212…

AgonistMaleIndolessGCmedicine.drug_classmedicine.medical_treatmentMorpholinesPharmacologyNaphthalenesSettore BIO/09 - FisiologiaHippocampusNitric oxideReceptor Cannabinoid CB2chemistry.chemical_compoundHippocampumedicineCannabinoid receptor type 2Inverse agonistAnimalsRats WistarReceptorCannabinoidCannabinoid Receptor AntagonistsCyclic GMPCannabinoid Receptor AgonistsElectrophysiology.ChemistryAntagonistElectric StimulationBenzoxazinesDisease Models AnimalNeurologyGuanylate CyclaseAnticonvulsantsNeurology (clinical)CannabinoidEpilepsies PartialSoluble guanylyl cyclaseTemporal Lobe Epilepsy AM630Epilepsy research
researchProduct